Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise

MT Newswires Live02-11

Oramed Pharmaceuticals (ORMP) said Tuesday that it signed definitive deals to form a joint venture with Hefei Tianhui Biotech that will bring Oramed's oral insulin to market and focus on its protein oral delivery technology.

The joint venture, to be named OraTech Pharmaceuticals, is expected to list on Nasdaq, according to Oramed.

The deals grant Oramed shareholders the right to receive a majority of Oramed's interest in OraTech, the company said.

Oramed also said it will invest $15 million in the joint venture, while Hefei Tianhui Biotech will contribute $60 million. Oramed will also transfer its oral insulin and POD technology, along with other assets, to OraTech, while Hefei Tianhui will supply the oral insulin capsules, the company added.

Shares of Oramed Pharmaceuticals were up over 24% in recent Tuesday trading.

Price: 2.71, Change: +0.54, Percent Change: +24.65

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2510339931?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-12 00:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510339931","market":"sg","top_or_hot":-1,"title":"Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Oramed Pharmaceuticals (ORMP) said Tuesday that it signed definitive deals to form a joint venture with Hefei Tianhui Biotech that will bring Oramed's oral insulin to market and focus on its protein oral delivery technology.</p><p>The joint venture, to be named OraTech Pharmaceuticals, is expected to list on Nasdaq, according to Oramed.</p><p>The deals grant Oramed shareholders the right to receive a majority of Oramed's interest in OraTech, the company said.</p><p>Oramed also said it will invest $15 million in the joint venture, while Hefei Tianhui Biotech will contribute $60 million. Oramed will also transfer its oral insulin and POD technology, along with other assets, to OraTech, while Hefei Tianhui will supply the oral insulin capsules, the company added.</p><p>Shares of Oramed Pharmaceuticals were up over 24% in recent Tuesday trading.</p><p>Price: 2.71, Change: +0.54, Percent Change: +24.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-12 00:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Oramed Pharmaceuticals (ORMP) said Tuesday that it signed definitive deals to form a joint venture with Hefei Tianhui Biotech that will bring Oramed's oral insulin to market and focus on its protein oral delivery technology.</p><p>The joint venture, to be named OraTech Pharmaceuticals, is expected to list on Nasdaq, according to Oramed.</p><p>The deals grant Oramed shareholders the right to receive a majority of Oramed's interest in OraTech, the company said.</p><p>Oramed also said it will invest $15 million in the joint venture, while Hefei Tianhui Biotech will contribute $60 million. Oramed will also transfer its oral insulin and POD technology, along with other assets, to OraTech, while Hefei Tianhui will supply the oral insulin capsules, the company added.</p><p>Shares of Oramed Pharmaceuticals were up over 24% in recent Tuesday trading.</p><p>Price: 2.71, Change: +0.54, Percent Change: +24.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JYNT","symbol_name":"The Joint Corp.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510339931","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510339931","pubTimestamp":1739290231,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Oramed Pharmaceuticals  said Tuesday that it signed definitive deals to form a joint venture with Hefei Tianhui Biotech that will bring Oramed's oral insulin to market and focus on its protein oral delivery technology.The joint venture, to be named OraTech Pharmaceuticals, is expected to list on Nasdaq, according to Oramed.The deals grant Oramed shareholders the right to receive a majority of Oramed's interest in OraTech, the company said.Oramed also said it will invest $15 million in the joint venture, while Hefei Tianhui Biotech will contribute $60 million. Oramed will also transfer its oral insulin and POD technology, along with other assets, to OraTech, while Hefei Tianhui will supply the oral insulin capsules, the company added.Shares of Oramed Pharmaceuticals were up over 24% in recent Tuesday trading.Price: 2.71, Change: +0.54, Percent Change: +24.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JYNT":"The Joint Corp.","BK4007":"制药","ORMP":"Oramed Pharmaceuticals Inc.","BK4185":"保健护理机构"},"translate_title":"Oramed Pharmaceuticals成立合资企业商业化口服胰岛素；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JYNT":1,"ORMP":1},"content_text":"Oramed Pharmaceuticals (ORMP) said Tuesday that it signed definitive deals to form a joint venture with Hefei Tianhui Biotech that will bring Oramed's oral insulin to market and focus on its protein oral delivery technology.The joint venture, to be named OraTech Pharmaceuticals, is expected to list on Nasdaq, according to Oramed.The deals grant Oramed shareholders the right to receive a majority of Oramed's interest in OraTech, the company said.Oramed also said it will invest $15 million in the joint venture, while Hefei Tianhui Biotech will contribute $60 million. Oramed will also transfer its oral insulin and POD technology, along with other assets, to OraTech, while Hefei Tianhui will supply the oral insulin capsules, the company added.Shares of Oramed Pharmaceuticals were up over 24% in recent Tuesday trading.Price: 2.71, Change: +0.54, Percent Change: +24.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510339931"}